Skip to main content
Publications

HVTN 123: A Phase 1, Randomized Trial Comparing Safety and Immunogenicity of CH505TF gp120 Produced by Stably and Transiently Transfected Cell Lines

By December 13, 2024June 9th, 2025No Comments